Across TCGA pan-cancer cohorts, LINC01558 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LINC01558 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher LINC01558 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC01558 expression acts as an unfavorable survival marker.
CESC are the cancer types where LINC01558 Mutation most reproducibly stratifies survival.